Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; the references it cites are not checked yet.

Ultrasound delivery of a TrkA agonist confers neuroprotection to Alzheimer-associated pathologies

Open access

Abstract

Early degeneration of basal forebrain cholinergic neurons contributes substantially to cognitive decline in Alzheimer’s disease. Evidence from preclinical models of neuronal injury and aging support a pivotal role for nerve growth factor (NGF) in neuroprotection, resilience, and cognitive function. However, whether NGF can provide therapeutic benefit in the presence of Alzheimer’s disease-related pathologies still unresolved. Perturbations in the NGF signalling system in Alzheimer’s disease may render neurons unable to benefit from NGF administration. Additionally, challenges related to brain delivery remain for clinical translation of NGF-based therapies in Alzheimer’s disease. To be safe and efficient, NGF-related agents should stimulate the NGF receptor, tropomyosin receptor kinase A (TrkA), avoid activation through the p75 neurotrophin receptor (p75NTR), and be delivered non-invasively to targeted brain areas using real-time monitoring. We addressed these limitations using MRI-guided focused ultrasound (MRIgFUS) to increase blood–brain barrier permeability locally and transiently, allowing an intravenously administered TrkA agonist that does not activate p75NTR, termed D3, to enter targeted brain areas. Here, we report the therapeutic potential of selective TrkA activation in a transgenic mouse model that recapitulates numerous Alzheimer’s disease-associated pathologies. Repeated MRIgFUS-mediated delivery of D3 (D3/FUS) improved cognitive function in the TgCRND8 model of Alzheimer’s disease. Mechanistically, D3/FUS treatment effectively attenuated cholinergic degeneration and promoted functional recovery. D3/FUS treatment also resulted in widespread reduction of brain amyloid pathology and dystrophic neurites surrounding amyloid plaques. Furthermore, D3/FUS markedly enhanced hippocampal neurogenesis in TgCRND8 mice, implicating TrkA agonism as a novel therapeutic target to promote neurogenesis in the context of Alzheimer’s disease-related pathology. Thus, this study provides evidence that selective TrkA agonism confers neuroprotection to effectively counteract Alzheimer’s disease-related vulnerability. Recent clinical trials demonstrate that non-invasive blood–brain barrier modulation using MRIgFUS is safe, feasible and reversible in Alzheimer’s disease patients. TrkA receptor agonists coupled with MRIgFUS delivery constitute a promising disease-modifying strategy to foster brain health and counteract cognitive decline in Alzheimer’s disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/awab460

Cites

Statistics

Figures

Figure 1 MRIgFUS-mediated delivery of D3 in TgCRND8 mice. (A) Mice were treated once weekly for 3 weeks, then tested on a variety of behavioural tasks. (B) Focused ultrasound experimental setup.21 (C) Neuroanatomical regions of interests (coloured circles) were selected on T2-weighted MRI. (D) BBB permeability in corresponding FUS-targeted areas was visualized over consecutive weeks on T1-weighted MRI following the influx of a gadolinium-based MRI contrast agent. (E) D3 and PBS/FUS-treated TgCRND8 mice exhibited deficits in nest building activity, which was improved by D3/FUS treatment. (F) TgCRND8 treated with D3/FUS displayed improved reference memory performance in the novel object recognition task relative to PBS/FUS and D3-treated TgCRND8 mice. (G) Total exploration time for both familiar and novel objects was similar across experimental groups. (H) In the Y maze, D3/FUS was the only treatment to prevent deficits in spontaneous alternation in TgCRND8 mice. (I) Total arm entries were comparable across treatment conditions. Scale bars in C and D = 5 mm. Statistics: (E) Repeated measures and (F–I) one-way ANOVA with Holm-Sidak post hoc test. Significance: *,+P < 0.05; **,++,††P < 0.01, ***,+++,†††P < 0.001. †Comparison of D3-treated TgCRND8 mice with PBS-treated non-Tg mice (genotype effect). +Comparison of PBS/FUS-treated with D3/FUS-treated TgCRND8 mice (D3 effect). *Comparison of D3-treated with D3/FUS-treated TgCRND8 mice (D3/FUS effect). Data represent means ± SEM; n = 10–12 per group.
Figure 1 MRIgFUS-mediated delivery of D3 in TgCRND8 mice. (A) Mice were treated once weekly for 3 weeks, then tested on a variety of behavioural tasks. (B) Focused ultrasound experimental setup.21 (C) Neuroanatomical regions of interests (coloured circles) were selected on T2-weighted MRI. (D) BBB permeability in corresponding FUS-targeted areas was visualized over consecutive weeks on T1-weighted MRI following the influx of a gadolinium-based MRI contrast agent. (E) D3 and PBS/FUS-treated TgCRND8 mice exhibited deficits in nest building activity, which was improved by D3/FUS treatment. (F) TgCRND8 treated with D3/FUS displayed improved reference memory performance in the novel object recognition task relative to PBS/FUS and D3-treated TgCRND8 mice. (G) Total exploration time for both familiar and novel objects was similar across experimental groups. (H) In the Y maze, D3/FUS was the only treatment to prevent deficits in spontaneous alternation in TgCRND8 mice. (I) Total arm entries were comparable across treatment conditions. Scale bars in C and D = 5 mm. Statistics: (E) Repeated measures and (F–I) one-way ANOVA with Holm-Sidak post hoc test. Significance: *,+P < 0.05; **,++,††P < 0.01, ***,+++,†††P < 0.001. †Comparison of D3-treated TgCRND8 mice with PBS-treated non-Tg mice (genotype effect). +Comparison of PBS/FUS-treated with D3/FUS-treated TgCRND8 mice (D3 effect). *Comparison of D3-treated with D3/FUS-treated TgCRND8 mice (D3/FUS effect). Data represent means ± SEM; n = 10–12 per group.CC BY-NC · PubMed Central
Figure 2 MRIgFUS-mediated delivery of D3 promotes spatial memory and cognitive flexibility in TgCRND8 mice. In the Barnes maze, D3/FUS enhanced spatial navigation in TgCRND8 mice relative to PBS/FUS and D3-treated TgCRND8 controls. (A) TgCRND8 mice demonstrated a slower learning curve relative to non-Tg mice, unless treated with D3/FUS. (B) Search strategies used by mice in the Barnes maze were classified. (C and D) Similar to non-Tg controls, D3/FUS-treated TgCRND8 mice used spatially-dependent search strategies to locate the escape box. (E–H) Performance in the probe test was improved by D3/FUS treatment, reflecting memory retention. This was demonstrated by (E) higher search density at the previous location of the escape box, (F) more time spent near the target hole in the absence of the escape box, (G) fewer entries in non-target holes (errors) and (H) higher search strategy scores of D3/FUS-treated TgCRND8 mice relative to PBS/FUS and D3-treated controls. (I–K) Barnes maze reversal learning, with the target hole relocated 180° from the original position, was improved by D3/FUS treatment in TgCRDN8 mice. (I) Relative to PBS/FUS and D3-treated TgCRND8 mice, non-Tg mice and D3/FUS-treated TgCRND8 mice demonstrated faster escape latency, (J) better spatially-dependent navigation as demonstrated by higher search strategy scores and (K) percentage of spatial strategies used across trial days. (L and M) Performance in the reversal probe test was improved in TgCRND8 mice following D3/FUS treatment, with (L) more time spent in the target zone and (M) higher search strategy score relative to D3-treated TgCRND8 mice. Statistics: (A, C, I and J) Repeated measures and (F–H, L and M) one-way ANOVA with Holm-Sidak post hoc test. Significance: *,+,†P < 0.05; **,++,††P < 0.01, ***,+++,†††P < 0.001. †Comparison of D3-treated TgCRND8 mice with PBS-treated non-Tg mice (genotype effect). +Comparison of PBS/FUS-treated with D3/FUS-treated TgCRND8 mice (D3 effect). *Comparison of D3-treated with D3/FUS-treated TgCRND8 mice (D3/FUS effect). Data represent means ± SEM; n = 10–12 per group.
Figure 2 MRIgFUS-mediated delivery of D3 promotes spatial memory and cognitive flexibility in TgCRND8 mice. In the Barnes maze, D3/FUS enhanced spatial navigation in TgCRND8 mice relative to PBS/FUS and D3-treated TgCRND8 controls. (A) TgCRND8 mice demonstrated a slower learning curve relative to non-Tg mice, unless treated with D3/FUS. (B) Search strategies used by mice in the Barnes maze were classified. (C and D) Similar to non-Tg controls, D3/FUS-treated TgCRND8 mice used spatially-dependent search strategies to locate the escape box. (E–H) Performance in the probe test was improved by D3/FUS treatment, reflecting memory retention. This was demonstrated by (E) higher search density at the previous location of the escape box, (F) more time spent near the target hole in the absence of the escape box, (G) fewer entries in non-target holes (errors) and (H) higher search strategy scores of D3/FUS-treated TgCRND8 mice relative to PBS/FUS and D3-treated controls. (I–K) Barnes maze reversal learning, with the target hole relocated 180° from the original position, was improved by D3/FUS treatment in TgCRDN8 mice. (I) Relative to PBS/FUS and D3-treated TgCRND8 mice, non-Tg mice and D3/FUS-treated TgCRND8 mice demonstrated faster escape latency, (J) better spatially-dependent navigation as demonstrated by higher search strategy scores and (K) percentage of spatial strategies used across trial days. (L and M) Performance in the reversal probe test was improved in TgCRND8 mice following D3/FUS treatment, with (L) more time spent in the target zone and (M) higher search strategy score relative to D3-treated TgCRND8 mice. Statistics: (A, C, I and J) Repeated measures and (F–H, L and M) one-way ANOVA with Holm-Sidak post hoc test. Significance: *,+,†P < 0.05; **,++,††P < 0.01, ***,+++,†††P < 0.001. †Comparison of D3-treated TgCRND8 mice with PBS-treated non-Tg mice (genotype effect). +Comparison of PBS/FUS-treated with D3/FUS-treated TgCRND8 mice (D3 effect). *Comparison of D3-treated with D3/FUS-treated TgCRND8 mice (D3/FUS effect). Data represent means ± SEM; n = 10–12 per group.CC BY-NC · PubMed Central
Figure 3 Repeated MRIgFUS delivery of D3 improves basal forebrain cholinergic neuron structural integrity and function in TgCRND8 mice. (A) Representative confocal images from non-Tg PBS, TgCRND8 PBS, PBS/FUS, D3 or D3/FUS-treated mice, show ChAT+ neurons in the MS/DBB and NBM. (B) Relative to non-TgCRND8, all groups of TgCRND8 mice had a comparable number of ChAT+ BFCNs. (C) Soma size, (D) mean neurite length, (E) total surface area and (F) branching complexity were decreased in ChAT+ BFCNs of PBS-treated TgCRND8 mice compared to non-Tg littermates, and increased with D3/FUS treatment. (G) ChAT enzyme activity was enhanced by D3/FUS in TgCRND8 mice and comparable to non-Tg levels. Scale bars in A = 100 μm; i–v = 30 μm. Statistics: one-way ANOVA with Holm-Sidak post hoc test. Significance: *,+,†P < 0.05; **,++,††P < 0.01, ***,+++,†††P < 0.001. †Comparison of PBS-treated TgCRND8 mice with PBS-treated non-Tg mice (genotype effect). +Comparison of PBS/FUS-treated with D3/FUS-treated TgCRND8 mice (D3 effect). *Comparison of PBS and D3-treated TgCRND8 mice with D3/FUS-treated TgCRND8 mice as shown (D3/FUS effect). Data represent means ± SEM; n = 4–6 per group.
Figure 3 Repeated MRIgFUS delivery of D3 improves basal forebrain cholinergic neuron structural integrity and function in TgCRND8 mice. (A) Representative confocal images from non-Tg PBS, TgCRND8 PBS, PBS/FUS, D3 or D3/FUS-treated mice, show ChAT+ neurons in the MS/DBB and NBM. (B) Relative to non-TgCRND8, all groups of TgCRND8 mice had a comparable number of ChAT+ BFCNs. (C) Soma size, (D) mean neurite length, (E) total surface area and (F) branching complexity were decreased in ChAT+ BFCNs of PBS-treated TgCRND8 mice compared to non-Tg littermates, and increased with D3/FUS treatment. (G) ChAT enzyme activity was enhanced by D3/FUS in TgCRND8 mice and comparable to non-Tg levels. Scale bars in A = 100 μm; i–v = 30 μm. Statistics: one-way ANOVA with Holm-Sidak post hoc test. Significance: *,+,†P < 0.05; **,++,††P < 0.01, ***,+++,†††P < 0.001. †Comparison of PBS-treated TgCRND8 mice with PBS-treated non-Tg mice (genotype effect). +Comparison of PBS/FUS-treated with D3/FUS-treated TgCRND8 mice (D3 effect). *Comparison of PBS and D3-treated TgCRND8 mice with D3/FUS-treated TgCRND8 mice as shown (D3/FUS effect). Data represent means ± SEM; n = 4–6 per group.CC BY-NC · PubMed Central
Figure 4 MRIgFUS-mediated delivery of D3 enhances cholinergic function in hippocampal and cortical areas. (A) Representative confocal images from non-Tg PBS, TgCRND8 PBS, PBS/FUS, D3 or D3/FUS-treated mice at 6.5 months of age show ChAT+ fibres in the hippocampus and prefrontal cortex. A decrease in ChAT+ fibre density in CA1 subfield of the hippocampus was apparent in PBS-treated TgCRND8 mice relative to non-Tg mice. A decrease in cholinergic innervation was also found across cortical layers in PBS-treated TgCRND8 mice compared to non-Tg controls. D3/FUS treatment increased cholinergic innervation throughout the prefrontal cortex and CA1. (B–D) D3/FUS promoted (B) basal and depolarization–induced ACh release from hippocampal and cortical slices, (C) tissue ACh content in the hippocampus and cortex and (D) AChE activity in these regions. Scale bar in A = 50 μm. Statistics: (B) two-way or (C and D) one-way ANOVA with Holm-Sidak post hoc test. Significance: *,+,†,#P < 0.05; **,++,††,##P < 0.01, ***,+++,†††,###P < 0.001; #Comparison with basal ACh release of the same treatment group (depolarization effect). †Comparison of D3-treated TgCRND8 mice with PBS-treated non-Tg mice (genotype effect). +Comparison of PBS/FUS-treated with D3/FUS-treated TgCRND8 mice (D3 effect). *Comparison of D3-treated TgCRND8 mice with D3/FUS-treated TgCRND8 mice (D3/FUS effect). Data represent means ± SEM; n = 6 per group. or = stratum oriens; pyr = stratum pyrimidale; rad = stratum radiatum; lm = stratum lacunosum moleculare.
Figure 4 MRIgFUS-mediated delivery of D3 enhances cholinergic function in hippocampal and cortical areas. (A) Representative confocal images from non-Tg PBS, TgCRND8 PBS, PBS/FUS, D3 or D3/FUS-treated mice at 6.5 months of age show ChAT+ fibres in the hippocampus and prefrontal cortex. A decrease in ChAT+ fibre density in CA1 subfield of the hippocampus was apparent in PBS-treated TgCRND8 mice relative to non-Tg mice. A decrease in cholinergic innervation was also found across cortical layers in PBS-treated TgCRND8 mice compared to non-Tg controls. D3/FUS treatment increased cholinergic innervation throughout the prefrontal cortex and CA1. (B–D) D3/FUS promoted (B) basal and depolarization–induced ACh release from hippocampal and cortical slices, (C) tissue ACh content in the hippocampus and cortex and (D) AChE activity in these regions. Scale bar in A = 50 μm. Statistics: (B) two-way or (C and D) one-way ANOVA with Holm-Sidak post hoc test. Significance: *,+,†,#P < 0.05; **,++,††,##P < 0.01, ***,+++,†††,###P < 0.001; #Comparison with basal ACh release of the same treatment group (depolarization effect). †Comparison of D3-treated TgCRND8 mice with PBS-treated non-Tg mice (genotype effect). +Comparison of PBS/FUS-treated with D3/FUS-treated TgCRND8 mice (D3 effect). *Comparison of D3-treated TgCRND8 mice with D3/FUS-treated TgCRND8 mice (D3/FUS effect). Data represent means ± SEM; n = 6 per group. or = stratum oriens; pyr = stratum pyrimidale; rad = stratum radiatum; lm = stratum lacunosum moleculare.CC BY-NC · PubMed Central
Figure 5 MRIgFUS BBB modulation combined with D3 delivery increases proliferation and survival of newborn neurons in TgCRND8 mice. (A) Following the last weekly treatment, separate cohorts of mice were injected with BrdU and sacrificed after 6 days and 28 days to label proliferating and surviving cells, respectively. (B) A representative confocal image of a BrdU (red), DCX (green), and DAPI (blue) labelled section 24 h after the last BrdU injection. (C) PBS/FUS-treated and D3/FUS-treated mice had more BrdU+ proliferating cells compared to PBS-treated TgCRND8 controls. (D) TgCRND8 mice had significantly fewer BrdU+ proliferating cells co-labelled with the immature neuronal marker DCX. This deficit was rescued by PBS/FUS and D3/FUS treatments. (E) Neuronal migration, as measured by the distribution of BrdU-labelled cells within the granule cell layer was impaired in TgCRND8 mice, and restored following D3/FUS treatment. (F) A representative confocal image of a BrdU (red) and NeuN (green) labelled section 28 days after the last treatment. (G) There was a significant genotype deficit in the number of surviving BrdU+ cells, (H) BrdU+ cells co-labelled with the mature neuronal marker NeuN, and (I) migration into the granule cell layer, which were increased in D3/FUS-treated mice. Statistics: (C–E, G–I) one-way ANOVA with Holm-Sidak post hoc test. Significance: *,^,+,†P < 0.05; **,^^,††P < 0.01, ***P < 0.001; †Comparison of PBS-treated non-Tg mice with PBS-treated TgCRND8 mice (genotype effect); ^Comparison of PBS-treated TgCRND8 mice with PBS/FUS-treated TgCRND8 mice (FUS effect); +Comparison of PBS/FUS-treated with D3/FUS-treated TgCRND8 mice (D3 effect). *Comparison of PBS and D3-treated TgCRND8 mice with D3/FUS-treated TgCRND8 mice as shown (D3/FUS effect). Data represent means ± SEM; n = 6 per group. oml = outer molecular layer; iml = inner molecular layer; gcl = granule cell layer; sgz = subgranular zone; hil = hilus; igl = inner granule layer; mgl = middle granule layer; ogl = outer granule layer.
Figure 5 MRIgFUS BBB modulation combined with D3 delivery increases proliferation and survival of newborn neurons in TgCRND8 mice. (A) Following the last weekly treatment, separate cohorts of mice were injected with BrdU and sacrificed after 6 days and 28 days to label proliferating and surviving cells, respectively. (B) A representative confocal image of a BrdU (red), DCX (green), and DAPI (blue) labelled section 24 h after the last BrdU injection. (C) PBS/FUS-treated and D3/FUS-treated mice had more BrdU+ proliferating cells compared to PBS-treated TgCRND8 controls. (D) TgCRND8 mice had significantly fewer BrdU+ proliferating cells co-labelled with the immature neuronal marker DCX. This deficit was rescued by PBS/FUS and D3/FUS treatments. (E) Neuronal migration, as measured by the distribution of BrdU-labelled cells within the granule cell layer was impaired in TgCRND8 mice, and restored following D3/FUS treatment. (F) A representative confocal image of a BrdU (red) and NeuN (green) labelled section 28 days after the last treatment. (G) There was a significant genotype deficit in the number of surviving BrdU+ cells, (H) BrdU+ cells co-labelled with the mature neuronal marker NeuN, and (I) migration into the granule cell layer, which were increased in D3/FUS-treated mice. Statistics: (C–E, G–I) one-way ANOVA with Holm-Sidak post hoc test. Significance: *,^,+,†P < 0.05; **,^^,††P < 0.01, ***P < 0.001; †Comparison of PBS-treated non-Tg mice with PBS-treated TgCRND8 mice (genotype effect); ^Comparison of PBS-treated TgCRND8 mice with PBS/FUS-treated TgCRND8 mice (FUS effect); +Comparison of PBS/FUS-treated with D3/FUS-treated TgCRND8 mice (D3 effect). *Comparison of PBS and D3-treated TgCRND8 mice with D3/FUS-treated TgCRND8 mice as shown (D3/FUS effect). Data represent means ± SEM; n = 6 per group. oml = outer molecular layer; iml = inner molecular layer; gcl = granule cell layer; sgz = subgranular zone; hil = hilus; igl = inner granule layer; mgl = middle granule layer; ogl = outer granule layer.CC BY-NC · PubMed Central
Figure 6 MRIgFUS-mediated delivery of D3 restores the dendritic complexity of newborn neurons in TgCRND8 mice. (A) Representative reconstructions of DCX+ cells across experimental groups to assess morphology of newborn granule neurons. (B) Decreased total dendritic length and (C) apical dendrite length in TgCRND8 mice was restored by D3/FUS treatment. (D) Sholl analysis of dendritic complexity demonstrated a left shift of the curve in PBS-treated TgCRND8 mice, which was normalized by D3/FUS treatment. (E) There was a positive correlation between total dendritic length of DCX+ fibres and ChAT+ fibre density in the outer molecular layer (OML), (F) inner molecular layer (IML) and (G) granule cell layer (GCL) subregions of the dentate gyrus. Scale bars = 30 μm. Statistics: (B and C) one-way and (D) two-way ANOVA with Holm-Sidak post hoc test. (E–G) Linear regression analysis. Dashed lines indicate a 95% confidence interval. Significance: ^,+P < 0.05; ^^,++P < 0.01, ***,+++, †††P < 0.001; †Comparison of PBS-treated non-Tg mice with PBS-treated TgCRND8 mice (genotype effect). ^Comparison of PBS-treated TgCRND8 mice with PBS/FUS-treated TgCRND8 mice (FUS effect). +Comparison of PBS/FUS-treated with D3/FUS-treated TgCRND8 mice (D3 effect). *Comparison of PBS and D3-treated TgCRND8 mice with D3/FUS-treated TgCRND8 mice as shown (D3/FUS effect). Data represent means ± SEM; n = 6 per group.
Figure 6 MRIgFUS-mediated delivery of D3 restores the dendritic complexity of newborn neurons in TgCRND8 mice. (A) Representative reconstructions of DCX+ cells across experimental groups to assess morphology of newborn granule neurons. (B) Decreased total dendritic length and (C) apical dendrite length in TgCRND8 mice was restored by D3/FUS treatment. (D) Sholl analysis of dendritic complexity demonstrated a left shift of the curve in PBS-treated TgCRND8 mice, which was normalized by D3/FUS treatment. (E) There was a positive correlation between total dendritic length of DCX+ fibres and ChAT+ fibre density in the outer molecular layer (OML), (F) inner molecular layer (IML) and (G) granule cell layer (GCL) subregions of the dentate gyrus. Scale bars = 30 μm. Statistics: (B and C) one-way and (D) two-way ANOVA with Holm-Sidak post hoc test. (E–G) Linear regression analysis. Dashed lines indicate a 95% confidence interval. Significance: ^,+P < 0.05; ^^,++P < 0.01, ***,+++, †††P < 0.001; †Comparison of PBS-treated non-Tg mice with PBS-treated TgCRND8 mice (genotype effect). ^Comparison of PBS-treated TgCRND8 mice with PBS/FUS-treated TgCRND8 mice (FUS effect). +Comparison of PBS/FUS-treated with D3/FUS-treated TgCRND8 mice (D3 effect). *Comparison of PBS and D3-treated TgCRND8 mice with D3/FUS-treated TgCRND8 mice as shown (D3/FUS effect). Data represent means ± SEM; n = 6 per group.CC BY-NC · PubMed Central
Figure 7 MRIgFUS-mediated delivery of D3 reduces amyloid plaque deposition and cholinergic dystrophic neurites in the cortex and hippocampus. (A) Representative confocal images from the hippocampus of PBS, PBS/FUS, D3 and D3/FUS-treated TgCRND8 mice stained for amyloid-β (red). (B) Total hippocampal surface area occupied by amyloid-β, (C) density of plaques and (D) mean plaque size were reduced in D3/FUS-treated mice relative to PBS, PBS/FUS and D3-treated mice. (E) A range of plaque sizes were decreased by D3/FUS treatment relative to PBS-treated controls. (F) The number of large plaques defined by an area >2000 μm2 were reduced in PBS/FUS and D3/FUS-treated mice. (G) Representative amyloid-β staining from cortical brain sections. (H) D3/FUS treatment decreased cortical amyloid coverage, (I) density of plaques, and (J) mean plaque size. (K) A range of plaques sizes decreased by D3/FUS treatment relative to PBS-treated controls. (L) PBS/FUS treatment preferentially reduced the number of large plaques. (M) Representative confocal images of ChAT-immunostained dystrophic neurites (green) surrounding plaques labelled with Thioflavin S (red). (N) D3/FUS treatment decreased the total hippocampal area occupied by clusters of dystrophic neurites and (O) number of clusters, (P) but not the mean ChAT+ area per cluster relative to D3-treated controls. (Q) Quantitative analysis in the cortex revealed the same trend in cluster area, (R) cluster number (S) and mean area per cluster. Scale bars in A, G and M = 100 μm; i and ii = 30 μm. Statistics: (B–D, F, H–J and L) one-way and (E and K) two-way ANOVA with Holm-Sidak post hoc test; (N–P and Q–S) unpaired Student’s t-test. Significance: *,^,+P < 0.05; **,^^,+P < 0.01, ** P < 0.001. ^Comparison of PBS-treated mice with PBS/FUS-treated TgCRND8 mice (FUS effect). +Comparison of PBS/FUS-treated with D3/FUS-treated TgCRND8 mice (D3 effect). *Comparison of PBS or D3-treated TgCRND8 mice with D3/FUS-treated TgCRND8 mice as shown (D3/FUS effect). Data are presented as mean ± SEM; n = 6 per group.
Figure 7 MRIgFUS-mediated delivery of D3 reduces amyloid plaque deposition and cholinergic dystrophic neurites in the cortex and hippocampus. (A) Representative confocal images from the hippocampus of PBS, PBS/FUS, D3 and D3/FUS-treated TgCRND8 mice stained for amyloid-β (red). (B) Total hippocampal surface area occupied by amyloid-β, (C) density of plaques and (D) mean plaque size were reduced in D3/FUS-treated mice relative to PBS, PBS/FUS and D3-treated mice. (E) A range of plaque sizes were decreased by D3/FUS treatment relative to PBS-treated controls. (F) The number of large plaques defined by an area >2000 μm2 were reduced in PBS/FUS and D3/FUS-treated mice. (G) Representative amyloid-β staining from cortical brain sections. (H) D3/FUS treatment decreased cortical amyloid coverage, (I) density of plaques, and (J) mean plaque size. (K) A range of plaques sizes decreased by D3/FUS treatment relative to PBS-treated controls. (L) PBS/FUS treatment preferentially reduced the number of large plaques. (M) Representative confocal images of ChAT-immunostained dystrophic neurites (green) surrounding plaques labelled with Thioflavin S (red). (N) D3/FUS treatment decreased the total hippocampal area occupied by clusters of dystrophic neurites and (O) number of clusters, (P) but not the mean ChAT+ area per cluster relative to D3-treated controls. (Q) Quantitative analysis in the cortex revealed the same trend in cluster area, (R) cluster number (S) and mean area per cluster. Scale bars in A, G and M = 100 μm; i and ii = 30 μm. Statistics: (B–D, F, H–J and L) one-way and (E and K) two-way ANOVA with Holm-Sidak post hoc test; (N–P and Q–S) unpaired Student’s t-test. Significance: *,^,+P < 0.05; **,^^,+P < 0.01, ** P < 0.001. ^Comparison of PBS-treated mice with PBS/FUS-treated TgCRND8 mice (FUS effect). +Comparison of PBS/FUS-treated with D3/FUS-treated TgCRND8 mice (D3 effect). *Comparison of PBS or D3-treated TgCRND8 mice with D3/FUS-treated TgCRND8 mice as shown (D3/FUS effect). Data are presented as mean ± SEM; n = 6 per group.CC BY-NC · PubMed Central
Figure 8 Locomotor function, anxiety-like behaviour and body weight are not affected following MRIgFUS-mediated delivery of D3. (A) BBB permeability was visualized by the influx of a gadolinium-based MRI contrast agent in sonicated focal spots (red circles). (B) The relative contrast enhancement and (C) sonication pressure were comparable between PBS/FUS and D3/FUS-treated mice, and across repeated sonications. (D) Heat map of general locomotor activity in the open field test. (E) Motor function measured by total distance travelled and (F) average velocity over a 10 min trial was similar across experimental groups. (G) No differences in anxiety-related behaviours were observed across treatment conditions, including time spent in the centre zone and (H) and number of rearing events. (I) Performance in the marble burying test was not impaired; the number of marbles submerged and (J) marbles buried were comparable in all conditions. (K) TgCRND8 mice weighed less than non-Tg mice throughout the study and body weight was not affected by repeated PBS/FUS, D3 or D3/FUS treatment. Scale bar in A = 5 mm. Statistics: (B, C and K) Repeated measures or (E–J) one-way ANOVA with Holm-Sidak post hoc test. Significance: †††P < 0.001. †Comparison of D3/FUS-treated TgCRND8 mice with PBS-treated non-Tg mice (genotype effect). Data represent means ± SEM; (B and C) n = 22–24 per group, (E–K) n = 10–12 per group.
Figure 8 Locomotor function, anxiety-like behaviour and body weight are not affected following MRIgFUS-mediated delivery of D3. (A) BBB permeability was visualized by the influx of a gadolinium-based MRI contrast agent in sonicated focal spots (red circles). (B) The relative contrast enhancement and (C) sonication pressure were comparable between PBS/FUS and D3/FUS-treated mice, and across repeated sonications. (D) Heat map of general locomotor activity in the open field test. (E) Motor function measured by total distance travelled and (F) average velocity over a 10 min trial was similar across experimental groups. (G) No differences in anxiety-related behaviours were observed across treatment conditions, including time spent in the centre zone and (H) and number of rearing events. (I) Performance in the marble burying test was not impaired; the number of marbles submerged and (J) marbles buried were comparable in all conditions. (K) TgCRND8 mice weighed less than non-Tg mice throughout the study and body weight was not affected by repeated PBS/FUS, D3 or D3/FUS treatment. Scale bar in A = 5 mm. Statistics: (B, C and K) Repeated measures or (E–J) one-way ANOVA with Holm-Sidak post hoc test. Significance: †††P < 0.001. †Comparison of D3/FUS-treated TgCRND8 mice with PBS-treated non-Tg mice (genotype effect). Data represent means ± SEM; (B and C) n = 22–24 per group, (E–K) n = 10–12 per group.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 69 · Cited by 43

Metadata

Authors
Xhima, K., Markham-Coultes, K., Hahn Kofoed, R., Saragovi, H. U., Hynynen, K., & Aubert, I.
Affiliations
  • University of Toronto (CA)
  • Sunnybrook Research Institute (CA)
  • Hurvitz Brain Sciences Research Program, Biological Sciences, Sunnybrook Research Institute , Toronto, ON M4N 3M5 , Canada
  • Jewish General Hospital (CA)
Corresponding author
Aubert, Isabelle
Venue
Brain
Published
2021-12-17
Volume
145
Issue
8
Pages
2806-2822
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W4200568963
Cited by
43
References
69
Citations by year
2026: 10 · 2025: 10 · 2024: 5 · 2023: 11 · 2022: 7
FWCI
3.61
Type
journal article
Language
en
Open access
Locations
  • Brain (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • Canadian Institutes of Health Research (FRN-93603, FDN-154272)
  • National Institute of Biomedical Imaging and Bioengineering (RO1-EB003268)
  • Sunnybrook Health Sciences Centre
  • FDC Foundation
  • WB Family Foundation
  • Gerald and Carla Connor
  • Weston Brain Institute (TR130117, GSD-152271)
  • Alzheimer Society of Canada
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Physical Sciences › Engineering › Biomedical Engineering › Ultrasound and Hyperthermia Applications
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
Alzheimer's disease, nerve growth factor, MR-guided focused ultrasound, blood-brain barrier permeability, p75 neurotrophin receptor, cholinergic neuron degeneration, TgCRND8 mice, amyloid plaques, dystrophic neurites, hippocampal neurogenesis, cognitive decline, neuroprotection
MeSH terms
Neuroprotection, Alzheimer Disease, Animals, Tropomyosin, Receptor, Nerve Growth Factor, Receptor, trkA, Nerve Growth Factor, Mice, Cholinergic Neurons

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ultrasound delivery of a TrkA agonist confers neuroprotection to Alzheimer-associated pathologies. https://app.cochat.ai/papers/10.1093/brain/awab460
The paper
Xhima, K., Markham-Coultes, K., Hahn Kofoed, R., Saragovi, H. U., Hynynen, K., & Aubert, I. (2022). Ultrasound delivery of a TrkA agonist confers neuroprotection to Alzheimer-associated pathologies. Brain. https://doi.org/10.1093/brain/awab460

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.